Grifols Competitors

Alexion Pharmaceuticals (NASDAQ:ALXN) and Grifols (NASDAQ:GRFS) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Profitability

This table compares Alexion Pharmaceuticals and Grifols' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Alexion Pharmaceuticals and Grifols' revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher earnings, but lower revenue than Grifols. Grifols is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Alexion Pharmaceuticals and Grifols, as provided by MarketBeat.com.

Alexion Pharmaceuticals presently has a consensus target price of $158.0476, suggesting a potential downside of 6.97%. Given Alexion Pharmaceuticals' higher probable upside, research analysts clearly believe Alexion Pharmaceuticals is more favorable than Grifols.

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Insider and Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Alexion Pharmaceuticals beats Grifols on 12 of the 14 factors compared between the two stocks.

BeiGene (NASDAQ:BGNE) and Grifols (NASDAQ:GRFS) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Profitability

This table compares BeiGene and Grifols' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares BeiGene and Grifols' revenue, earnings per share (EPS) and valuation.

Grifols has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for BeiGene and Grifols, as provided by MarketBeat.com.

BeiGene presently has a consensus target price of $319.3750, suggesting a potential upside of 4.62%. Given BeiGene's higher probable upside, research analysts clearly believe BeiGene is more favorable than Grifols.

Volatility and Risk

BeiGene has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Insider and Institutional Ownership

60.7% of BeiGene shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. 9.0% of BeiGene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Grifols beats BeiGene on 8 of the 14 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Grifols (NASDAQ:GRFS) are both large-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Profitability

This table compares Royalty Pharma and Grifols' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Royalty Pharma and Grifols' gross revenue, earnings per share and valuation.

Grifols has higher revenue and earnings than Royalty Pharma.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Grifols pays an annual dividend of $0.14 per share and has a dividend yield of 0.8%. Grifols pays out 12.0% of its earnings in the form of a dividend. Royalty Pharma has raised its dividend for 1 consecutive years. Royalty Pharma is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Royalty Pharma and Grifols, as provided by MarketBeat.com.

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 24.04%. Given Royalty Pharma's higher probable upside, research analysts clearly believe Royalty Pharma is more favorable than Grifols.

Institutional and Insider Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 15.2% of Grifols shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genmab A/S (NASDAQ:GMAB) and Grifols (NASDAQ:GRFS) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Earnings & Valuation

This table compares Genmab A/S and Grifols' revenue, earnings per share (EPS) and valuation.

Grifols has higher revenue and earnings than Genmab A/S. Grifols is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Genmab A/S and Grifols' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Genmab A/S and Grifols, as provided by MarketBeat.com.

Genmab A/S presently has a consensus target price of $41.5714, suggesting a potential upside of 13.21%. Given Genmab A/S's higher probable upside, research analysts clearly believe Genmab A/S is more favorable than Grifols.

Volatility and Risk

Genmab A/S has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Summary

Genmab A/S beats Grifols on 8 of the 13 factors compared between the two stocks.

Grifols (NASDAQ:GRFS) and CureVac (NASDAQ:CVAC) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.

Earnings and Valuation

This table compares Grifols and CureVac's revenue, earnings per share and valuation.

Grifols has higher revenue and earnings than CureVac.

Insider and Institutional Ownership

15.2% of Grifols shares are owned by institutional investors. Comparatively, 4.3% of CureVac shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Grifols and CureVac's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for Grifols and CureVac, as reported by MarketBeat.

CureVac has a consensus target price of $58.3333, suggesting a potential downside of 42.20%. Given CureVac's higher possible upside, analysts clearly believe CureVac is more favorable than Grifols.

Summary

Grifols beats CureVac on 7 of the 8 factors compared between the two stocks.

Grifols (NASDAQ:GRFS) and Horizon Therapeutics Public (NASDAQ:HZNP) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.

Earnings and Valuation

This table compares Grifols and Horizon Therapeutics Public's revenue, earnings per share and valuation.

Grifols has higher revenue and earnings than Horizon Therapeutics Public. Grifols is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

15.2% of Grifols shares are owned by institutional investors. Comparatively, 88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Grifols and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for Grifols and Horizon Therapeutics Public, as reported by MarketBeat.

Horizon Therapeutics Public has a consensus target price of $111.3636, suggesting a potential upside of 24.50%. Given Horizon Therapeutics Public's stronger consensus rating and higher possible upside, analysts clearly believe Horizon Therapeutics Public is more favorable than Grifols.

Risk and Volatility

Grifols has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Grifols on 12 of the 14 factors compared between the two stocks.